Google Sniper

Showing posts with label Parkinson's Disease. Show all posts
Showing posts with label Parkinson's Disease. Show all posts

Monday, 27 February 2017

What is Parkinson's?

Parkinson's is a progressive neurological condition.
People with Parkinson's don't have enough of a chemical called dopamine because some nerve cells in their brain have died.
"Once I accepted myself as a person with Parkinson's, and did not think of myself as a lesser person because of this, other people did the same. It is not the most important thing about me".
Caroline, diagnosed in 2003
Without dopamine people can find that their movements become slower so it takes longer to do things.
The loss of nerve cells in the brain causes the symptoms of Parkinson's to appear.
There's currently no cure for Parkinson's and we don't yet know why people get the condition.
Parkinson's doesn't directly cause people to die, but symptoms do get worse over time.

How many people have Parkinson's?

One person in every 500 has Parkinson's. That's about 127,000 people in the UK.
Most people who get Parkinson's are aged 50 or over but younger people can get it too.

Parkinson's symptoms

Everyone with Parkinson's has different symptoms.
The main symptoms of Parkinson's are tremor, rigidity and slowness of movement.
As well as affecting movement, people with Parkinson's can find that other issues, such as tiredness, pain, depression and constipation, can have an impact on their day-to-day lives.
Symptoms and the speed at which the condition develops will differ from one person to the next.
The symptoms can be controlled using a combination of drugs, therapies and occasionally surgery.
Find out more about all Parkinson's symptoms.
As Parkinson's progresses, an increased amount of care and support may be required, although many people maintain a good quality of life with limited care or treatment.

Parkinson's diagnosis

"The Parkinson's nurse was immensely helpful – coming to my house when I was newly diagnosed and explaining Parkinson's to me so well".
Diana, diagnosed in 2004
It's not easy to diagnose Parkinson's. There are no laboratory tests so it's important that the diagnosis is made by a specialist.
The specialist will examine the person for any physical signs of Parkinson's and take a detailed history of the symptoms they're experiencing.
Find out more in our Diagnosing Parkinson's information sheet.
There are guidelines for the diagnosis of Parkinson's which health professionals should follow:
  • NICE Guideline (England, Wales, Northern Ireland)
  • SIGN (Scottish Intercollegiate Guidelines Network) Guideline

Source: https://www.parkinsons.org.uk/content/what-parkinsons

Sunday, 7 August 2016

Anxiety and Depression with Parkinson's Disease

When facing a diagnosis of Parkinson’s disease, it is understandable to feel anxious or depressed. But mood disorders such as anxiety and depression are real clinical symptoms of Parkinson’s, just as rigidity and tremor. In fact, at least half of all Parkinson’s patients may suffer from clinical depression at some point during the course of their disease, according to some estimates.
The good news: Over the past decade, researchers have placed increasing focus on investigating these aspects of the disease, and today we have a better understanding of how to treat mood disorders in Parkinson’s and increase quality of life.
On this page you’ll find up-to-date information from clinicians and researchers, as well as quotes from our Guide for the Newly Diagnosed, authored by Parkinson’s patients themselves as a resource for those just beginning their journey with Parkinson’s disease. We’ve also included various multimedia interviews with Dr. Irene Hegeman Richard, MD, of the University of Rochester School of Medicine and Dentistry and our Scientific Advisory Board, who has done extensive research into depression and Parkinson’s disease.
 How Can I Get Help for Depression or Anxiety?
“While depression and anxiety can be normal reactions to being diagnosed with a serious disease, clinical depression is real. These symptoms, if left untreated, are damaging at best and deadly at worst. Make sure you discuss depression and anxiety with your doctor. It is important to remember that clinical depression and anxiety are underdiagnosed in people with Parkinson’s and that they are symptoms of your disease, not character flaws.”
 
Depression can be seriously detrimental, and, for people with Parkinson’s, it can affect long-term outcomes for the worse by hindering critical elements of an overall treatment regimen such as staying socially connected, exercising to manage motor symptoms, or being proactive about seeking care.
Be on the lookout for a lack of enjoyment in activities and situations that once brought you joy. Also pay attention to observations made by family and friends because you or your physician may not always recognize the signs of depression and anxiety. In fact, your physician may not even ask you about these conditions if you don’t mention changes in mood or outlook.
Depression and anxiety can be treated with medications, lifestyle changes and therapy or counseling from a qualified practitioner. Support groups may also be source of help.

What Does the Research Tell Us?

“Even within the past decade, quality of life for Parkinson's patients has greatly improved. The prospects for the next five to 10 years are even better.” 
Researchers believe that depression and anxiety in Parkinson’s disease may be due to the underlying changes in brain chemistry and circuitry that are caused by the disease itself.  In fact, depression in Parkinson’s patients can start before motor symptoms even arise. The Michael J. Fox Foundation actively pursues research that can shed light on the connection between depression and Parkinson’s, and lead to treatment breakthroughs for everyone living with the disease.

The same pathways that create dopamine in the brain — which are impacted in Parkinson’s disease — also create the hormonal neurotransmitter serotonin. Serotonin regulates mood, appetite and sleep. If dopamine is like the motor oil to keep the body’s systems controlling movement running smoothly, then serotonin is like the motor oil for a person’s mood. Researchers hypothesize that the effect of Parkinson’s on this system is responsible for the clinical symptoms of depression and anxiety. The Foundation is supporting research to clarify this relationship.
In April 2012, the Study of Antidepressants in Parkinson's Disease (SAD-PD), the first major clinical study testing common antidepressants in people with Parkinson’s, found that some of these drugs can ease depression in Parkinson’s patients without aggravating motor symptoms.* Needless to say, work closely with your physician before adding any drug to your Parkinson’s treatment regimen.
“A Parkinson’s diagnosis, although life-altering, is not a death sentence. Symptoms will change over time, as will your attitude; no one should expect, nor should you expect from yourself, that this will be easy to deal with. But people with Parkinson’s and others alike should all value and make the most of every day. In a best-case scenario, a Parkinson’s diagnosis can become a real wake-up call: a chance to re-examine your priorities, and focus not on what you cannot do, but instead, on what you can.”
*A specific note on drug interactions: It is critical that patients with Parkinson’s disease educate themselves and work closely with their physicians and medical team to understand potential drug interactions between antidepressants and Parkinson’s treatments. The results of combining incompatible drugs can be serious.  

Source: https://www.michaeljfox.org/understanding-parkinsons/living-with-pd/topic.php?emotions-depression&navid=emotions-depression&smcid=ag-a30U0000000OWEc&s_src=Adwords&s_subsrc=adwords_depression&gclid=CJ-rm-Cbr84CFfIV0wod_KMC8w

Tuesday, 17 December 2013

Researchers discover direct evidence of genetic overlap between cognitive ability and schizophrenia

Investigators at The Feinstein Institute for Medical Research have discovered for the first time, direct evidence of a genetic overlap between schizophrenia and general cognitive ability. The findings are published online in Molecular Psychiatry.
Schizophrenia is a chronic, severe and disabling brain disorder that affects approximately 2.2 million Americans each year. It is characterized by a significant reduction in general cognitive abilities, so that many patients struggle with completing school, holding jobs and achieving their full potential. Previous studies have indicated subtle cognitive abnormalities in undiagnosed and unmedicated relatives of patients who live with schizophrenia, which suggests the possibility of genetic overlap between risk for schizophrenia and cognitive traits. These previous studies, however, did not test this overlap on the molecular level.
Anil Malhotra, MD, director of psychiatry research at Zucker Hillside Hospital and an investigator at the Feinstein Institute, and his colleague Todd Lencz, PhD, associate investigator at the Zucker Hillside Hospital and the Feinstein Institute, conducted the first molecular genetic test to determine if genetic markers of reduced cognitive ability were also genetic markers of increased schizophrenia risk. Specifically, they conducted a large-scale, meta-analysis, genome-wide association study (GWAS) of samples from 5,000 subjects provided by the Cognitive Genomics consorTium (COGENT). COGENT, which was founded and is led by Dr. Malhotra, is an international consortium of nine teams of researchers across seven countries. Through their analysis, they confirmed that patients who suffered from schizophrenia also had lessened cognitive ability. This is the first direct evidence for genetic overlap between schizophrenia risk genes and genes that regulate general cognitive ability, such as memory, attention, and language abilities. The results provide molecular confirmation of this genetic overlap and additional insight into how schizophrenia develops and progresses.
"This research leads us to a deeper understanding of how schizophrenia affects the brain at the molecular level," said Dr. Lencz. "Our studies are designed to provide clues to the development of new treatments to improve the lives of our patients."
 
Source:  http://www.news-medical.net/news/20131217/Researchers-discover-direct-evidence-of-genetic-overlap-between-cognitive-ability-and-schizophrenia.aspx?page=2